- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
3M COMPANY / ACELITY
M.9426
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 1.2
Description of the concentration
On May 2, 2019, 3M announced that it had agreed to acquire the entire equity interest in Acelity from investment funds advised by Apax Partners LLP, funds advised by the Canada Pension Plan Investment Board, and funds advised by the Public Sector Pension Investment Board. The Transaction will result in 3M’s acquisition of sole control of Acelity. 3M expects the acquisition to enhance its medical solutions business and to support its growth strategy in advanced and surgical wound care solutions.
3M is a U.S.-based diversified technology company listed on the New York Stock Exchange.
Acelity is a U.S.-based company primarily active in the development and commercialization of advanced wound care products.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.